The Patient Protection and Affordable Care Act (PPACA) was signed into law in 2010 to contain increasing U.S. healthcare costs. The subsequent impact on pharmaceutical manufacturers in the U.S. is the emergent need to demonstrate the value of medicines for both the patient and the healthcare system as a whole. The purpose of this study was to determine how pharmaceutical manufacturers can apply lessons from quality and outcomes standards commonplace within European healthcare systems to better demonstrate value to the evolving U.S. healthcare system. We conducted a literature review using publicly available databases and web-based searches to examine cases where manufacturers played a role in improving quality and outcomes in European healthcare systems. We then assessed the US healthcare landscape to identify opportunities for application of these findings, given the emerging focus on value following implementation of the PPACA. We gained insights from European healthcare systems pertaining to healthcare quality outcomes that could be applied to the U.S. healthcare system. We found examples where attempts to improve healthcare quality have been delivered in partnership with pharmaceutical manufacturers. Pharmaceutical manufacturers can apply strategies currently seen in Europe to align with policy changes within the U.S. healthcare system. Demonstrating value and ensuring sustainability will require pharmaceutical manufacturers to work in partnership with payers, healthcare providers, and patients to ensure that the value of the treatments is fully realized and demonstrated to all stakeholders involved. The European value-based experience serves as a positive model and offers numerous examples of both value demonstration and care models, including the development of successful payer-manufacturer partnerships.  As the U.S. progresses along this same value-focused path, there is a significant and necessary role that manufacturers can play to drive higher value care and demonstrate better outcomes.